Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome
Authors:
- 21 January 2008
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (3) , 595
Abstract
POEMS is an acronym for a rare multisystemic syndrome encompassing polyneuropathy (P), organomegaly (O), endocrinopathy (E), monoclonal gammopathy (M), skin changes (S) and additional features variably expressed [1]. POEMS syndrome is associated with high vascular endothelial growth factor (VEGF) serum levels. This angiogenic factor likely plays a pathogenic role, in particular for neuropathy, possibly via alteration of endoneurial vessels [2]. Treatment options are still debated, but recently autologous stem-cell transplantation (ASCT) appears to be effective. This approach for POEMS patients, however, was associated with severe morbidity, mainly respiratory failures that appeared to be related to neuromuscular damage [3].Keywords
This publication has 5 references indexed in Scilit:
- Bevacizumab therapy for POEMS syndromeBlood, 2006
- Bevacizumab therapy for POEMS syndromeBlood, 2005
- Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesisBrain, 2005
- Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literatureBlood, 2004
- POEMS syndrome: definitions and long-term outcomeBlood, 2003